P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL

Bibliographic Details
Published in:	HemaSphere
Main Authors:	Yusuf Rasheed, Abu-Sayeef Mirza, Alexander Pine, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred Lee, Stuart Seropian
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972428.19857.ae

Similar Items

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
by: Abu-Sayeef Mirza, et al.
Published: (2023-08-01)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-10-01)

Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)

Lisocabtagene Maraleucel for Richter's Transformation—A Case Series
by: Courtney J. Smith, et al.
Published: (2025-04-01)

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
by: Guido Ghilardi, et al.
Published: (2024-04-01)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
by: Mi Kwon, et al.
Published: (2022-06-01)

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
by: Peter A. Riedell, et al.
Published: (2020-01-01)

Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient
by: Dasom Lee, et al.
Published: (2024-02-01)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
by: André Airosa Pardal, et al.
Published: (2025-10-01)

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
by: Alison Sehgal, et al.
Published: (2025-08-01)

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
by: Yuliya Linhares, et al.
Published: (2024-12-01)

Comparative efficacy of lisocabtagene maraleucel in the PILOT study <i>versus</i> second-line chemotherapy regimens in the real world
by: Nilanjan Ghosh, et al.
Published: (2024-10-01)

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
by: Frederick L. Locke, et al.
Published: (2025-06-01)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
by: Caron Jacobson, et al.
Published: (2023-08-01)

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
by: Leo I. Gordon, et al.
Published: (2023-08-01)

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
by: Soumya Poddar, et al.
Published: (2025-08-01)

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
by: Xuefeng Wang, et al.
Published: (2025-07-01)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
by: M. Dickinson, et al.
Published: (2022-06-01)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
by: Paolo Strati, et al.
Published: (2020-07-01)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
by: Andrew P. Jallouk, et al.
Published: (2022-11-01)

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
by: Loretta J. Nastoupil, et al.
Published: (2025-03-01)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
by: Concetta Rafaniello, et al.
Published: (2023-08-01)

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
by: Jennifer M. Logue, et al.
Published: (2020-04-01)

The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review
by: Zhen Sun, et al.
Published: (2021-04-01)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
by: Mohty R, et al.
Published: (2023-04-01)

Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
by: Mili Shah, et al.
Published: (2021-03-01)

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
by: Crystal Mackall, et al.
Published: (2024-07-01)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Nico Gagelmann, et al.
Published: (2023-08-01)

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States
by: Olalekan O. Oluwole, et al.
Published: (2024-05-01)

Chimeric antigen receptor T‐cell therapy in diffuse large B‐cell lymphoma: Evaluating axicabtagene ciloleucel in the ZUMA‐7 trial
by: Vadim Lesan, et al.
Published: (2025-03-01)

P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES
by: S. Boyle, et al.
Published: (2022-06-01)

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States
by: Na Li, et al.
Published: (2023-05-01)

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
by: Julie Rytlewski, et al.
Published: (2021-11-01)

Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
by: Graeme A. Fenton, et al.
Published: (2024-01-01)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
by: William G. Breen, et al.
Published: (2023-08-01)

Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01)

S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY
by: A. Sehgal, et al.
Published: (2022-06-01)

Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy
by: Yao Qi, et al.
Published: (2025-06-01)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
by: LI Wang, et al.
Published: (2023-08-01)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
by: Roch Houot, et al.
Published: (2023-08-01)